Skip to main content

Advertisement

SpringerLink
Log in

The Non-neurogenic Overactive Bladder: an Update

  • Urogynecology and Reconstructive Pelvic Surgery (S Vitale, Section Editor)
  • Published:
Current Obstetrics and Gynecology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The objective of this study was to review the most recent literature to evaluate and analyse new information regarding the evaluation and treatment trends that is available.

Recent Findings

The aetiology and pathophysiology for the non-neurogenic or idiopathic overactive bladder (OAB) remains unclear. Recent functional MRI studies of the brain indicate an age-related decrease in neurological control of continence of urine. Microbiomes in the urogenital tract have also been implicated in the aetiology of the OAB. The diagnosis and initial management should be based on a thorough history, examination and basic investigations to exclude treatable causes such as urinary tract infection (UTI) and malignant conditions. The first line of therapy is conservative with behavioural and pelvic floor muscle retraining and the addition of an information leaflet can add to a better outcome. However, there are still too few studies to evaluate the effect on urgency urinary incontinence (UUI). Electrical stimulation combined with pelvic floor muscle training (PFMT) treatment versus PFMT treatment alone is twice more likely to improve UUI. There is a recent trend towards mirabegron as the preferred choice of first-line pharmacotherapy versus anticholinergic treatment for OAB to avoid anticholinergic side effects. For the refractory cases, phase III trials with level 1 evidence make licencing of the use of 100 U of botulinum for the idiopathic OAB now possible. American Board of Urology (ABU)-certified urologists in the USA perform sacral neuromodulation (SNS) more commonly and very rarely augmentation cystoplasty.

Summary

The pathophysiology of the OAB remains unclear and further ongoing research is required. New trends of treatment are recognised for both conservative pharmacotherapy and refractory OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Haylen Bt, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN, International Urogynecological Association., International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29(1):4–20.

  2. ••Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142–73. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment https://doi.org/10.1016/j.juro.2015.01.087

    Article  Google Scholar 

  3. Drake M. The overactive bladder. In: Vol 2 Textbook of female urology and urogynecology. Fourth Edi. Cardozo L, Staskin D CRC Press 2017; 584–593.

  4. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–15.

    Article  Google Scholar 

  5. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.

    CAS  PubMed  Google Scholar 

  6. O’Dowd TC. Urinary incontinence in women: the management of urinary incontinence in women. Nice. 2013;43(375):426–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25340217

    Google Scholar 

  7. Chung E, Lee D, Gani J, Gillman M, Maher C, Brennan J, et al. Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder. Med J Aust. 2018;208(1):41–5.

    Article  Google Scholar 

  8. Gulur, Dev M and Drake MJ. Management of overactive bladder. CNS Spectr [Internet]. 2004;9(12):8. Available from: https://doi.org/10.1038/nrurol.2010.147

    Article  CAS  Google Scholar 

  9. Suskind AM. The aging overactive bladder: a review of aging-related changes from the brain to the bladder. Curr Bladder Dysfunct Rep. 2017;12(1):42–7.

    Article  Google Scholar 

  10. Brubaker L, Wolfe AJ. The female urinary microbiota/microbiome: clinical and research implications. Rambam Maimonides Med J [Internet]. 2017;8(2):e0015. Available from: http://www.rmmj.org.il/issues/33/articles/716.

    Article  Google Scholar 

  11. Curtiss N, Balachandran A, Krska L, Peppiatt-Wildman C, Wildman S, Duckett J. A case controlled study examining the bladder microbiome in women with overactive bladder (OAB) and healthy controls. Eur J Obstet Gynecol Reprod Biol [Internet]. 2017;214:31–5. Available from: https://doi.org/10.1016/j.ejogrb.2017.04.040.

    Article  Google Scholar 

  12. Petschow B, Doré J, Hibberd P, Dinan T, Reid G, Blaser M, et al. Probiotics, prebiotics, and the host microbiome: the science of translation. Ann N Y Acad Sci. 2013;1306(1):1–17.

    Article  CAS  Google Scholar 

  13. • Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol [Internet]. 2015;193(5):1572–80. CUA guideline on adult overactive bladder https://doi.org/10.5489/cuaj.4586

    Article  Google Scholar 

  14. Homma Y, Kakizaki H, Yamaguchi O, Yamanishi T, Nishizawa O, Yokoyama O, et al. Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology [Internet]. 2011;77(1):60–4. Available from: https://doi.org/10.1016/j.urology.2010.06.044.

    Article  Google Scholar 

  15. Gezginci E, Iyigun E, Yilmaz S. Comparison of 3 different teaching methods for a behavioral therapy program for female overactive bladder. J Wound, Ostomy Cont Nurs [Internet]. 2018;45(1):68–74. Available from: http://insights.ovid.com/crossref?an=00152192-201801000-00013.

    Article  Google Scholar 

  16. Allahdin S, Oo N. An overview of treatment of overactive bladder syndrome in women. J Obstet Gynaecol (Lahore). 2012;32(3):217–21.

    Article  CAS  Google Scholar 

  17. Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev. 2016;2016(12).

  18. Geoffrion R. No. 283-treatments for overactive bladder: focus on pharmacotherapy. J Obstet Gynaecol Canada. 2018;40:e22–32.

    Article  Google Scholar 

  19. Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120:562–75.

    Article  CAS  Google Scholar 

  20. Schiavi MC, Faiano P, D’Oria O, Zullo MA, Muzii L, Benedetti Panici P. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: a retrospective analysis. J Obstet Gynaecol Res 2017;

  21. Serati M, Leone Roberti Maggiore U, Sorice P, Cantaluppi S, Finazzi Agrò E, Ghezzi F. Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder? Int Urogynecol J. 2017;

  22. Alcántara Montero A. Propuesta de algoritmo de tratamiento para pacientes con síndrome de vejiga hiperactiva resistente a fármacos. Vol. 41, Actas Urologicas Espanolas. 2017. p. 657–8.

    Article  Google Scholar 

  23. Tadrous M, Elterman D, Khuu W, Mamdani MM, Juurlink DN, Gomes T. CUAJ – Original Research Tadrous et al OAB treatment patterns Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: an ecologic study. 2017; Available from: https://doi.org/10.5489/cuaj.4541.

  24. Henderson E, Drake M. Overactive bladder. Maturitas. 2010;66(3):257–62.

    Article  CAS  Google Scholar 

  25. Duthie J, Wilson D, Vincent M, Herbison G. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2007;(12).

  26. Gu H-Y, Song J-K, Zhang W-J, Xie J, Yao Q-S, Zeng W-J, et al. A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages. Oncotarget [Internet]. 2017 27;8(52):90338–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29163833.

  27. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol [Internet]. 2013 ;189(6):2186–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23246476.

    Article  CAS  Google Scholar 

  28. Eldred-Evans D, Sahai A. Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol [Internet]. 2017 Jan;9(1):3–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28042308.

  29. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol [Internet]. 2010 Apr;183(4):1438–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20171677.

    Article  Google Scholar 

  30. Monga A, Dmochowski R, Miller D. Evaluation of a novel, non-invasive, patient-managed neuromodulation system (PMNS) on urgency, urinary incontinence and patient-reported outcomes in subjects with overactive bladder (OAB) syndrome who had previously failed therapy: a four week, multicente. Int Cont Soc Annu Meet Glas. 2011;4(Table 2):67–9.

    Google Scholar 

  31. Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, et al. Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol [Internet]. 2018 Jan;199(1):229–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28709886.

    Article  Google Scholar 

  32. Elterman DS, Chughtai B, Vertosick E, Thomas D, Eastham J, Sandhu J. Trends and clinical practice patterns of sacral neuromodulation for overactive bladder. Female Pelvic Med Reconstr Surg [Internet]. 2017 Jun 27; Available from: http://www.ncbi.nlm.nih.gov/pubmed/28658001.

  33. Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women. Jama [Internet]. 2016;316(13):1366. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.14617.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stellenbosch University, Stellenbosch, South Africa

    Jacobus A. Van Rensburg & Farzana Cassim

Authors
  1. Jacobus A. Van Rensburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farzana Cassim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacobus A. Van Rensburg.

Ethics declarations

Conflict of Interest

Farzana Cassim declares no conflict of interest.

Jacobus A. Van Rensburg reports the following: he received remuneration from Earth Medical for accommodation in Pacific Hotel, Vancouver to attend FIGO 2015. Dr. Van Rensburg also received the registration fee from Boston Scientific for 41st IUGA international meeting in Cape Town RSA. Dr. Van Rensburg also received sponsorship with accommodation and air ticket to visit Pachabel manufacturing company of Probiotics in Liege, Belgium in July 2017. In October 2017, Dr. Van Rensburg received sponsorship for air fare and accommodation from Legacy Medical to visit expert surgical unit in Rome to complete the Dipromed course.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Urogynecology and Reconstructive Pelvic Surgery

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Van Rensburg, J.A., Cassim, F. The Non-neurogenic Overactive Bladder: an Update. Curr Obstet Gynecol Rep 7, 139–145 (2018). https://doi.org/10.1007/s13669-018-0248-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13669-018-0248-0

Keywords

Search

Navigation